Marinus Pharma (MRNS) Provides Business Outlook for 2020
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St set to snap three-day losing streak as stocks reclaim some shine
- Oil rises 1%, as US-Iran strikes risk limiting already impaired supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Marinus Provides Business Outlook for 2020
January 13, 2020 7:30 AM ESTEnrollment on-track for CDKL5 Deficiency Disorder Phase 3 readout Q3 2020
Two additional late-stage clinical trials planned to initiate in 2020
Company presentation and live webcast at 38th Annual J.P. Morgan Global Healthcare Conference on Thursday, January 16, 2020 at 11:00am PT
RADNOR, Pa., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (Marinus or Company), a pharmaceutical company dedicated... More
